Clinical Trial Update: Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients [Phase 4]

View source ↗

Summary

This Phase 4 trial update describes continuing somatostatin analogue therapy in patients with gastroenteropancreatic neuroendocrine tumors after progression and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor

Drugs mentioned

• SIGNIFOR (PASIREOTIDE)
• Sandostatin (Octreotide acetate)
• Sandostatin LAR (octreotide)
• Somatuline (lanreotide)

Snippet

Sponsor: University Hospital, Antwerp | Conditions: Gastroenteropancreatic Neuroendocrine Tumor | Phase 4 | Status: RECRUITING